Type
. Bophuthatswana's contribution towards the elimination of leprosy as a public health problem in southern Africa by the year 2000. Medicine and law. 1993;12(6-8):663-71.
Type
. [Tourism and risk of infection (author's transl)]. MMW, Munchener medizinische Wochenschrift. 1976;118(35):1061-8.
Type
. Presence of antibodies reacting with a ribonucleoprotein from Mycobacterium tuberculosis in sera from leprous patients. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie. 1976;234(1):68-71.
Type
. Public Health Reports, December 11, 1942: Sulfanilamide in the treatment of leprosy. Public health reports (Washington, D.C. : 1974). 1975;90(6):486-9.
Type
. A role for natural antibody in the pathogenesis of leprosy: antibody in nonimmune serum mediates C3 fixation to the Mycobacterium leprae surface and hence phagocytosis by human mononuclear phagocytes. Infection and immunity. 1994;62(1):280-9.
Type
. The role of the macrophage in resistance to the leprosy bacillus. Immunology series. 1994;60:281-302.
Type
. [Leprosy can be eliminated as a public health problem]. Lakartidningen. 1993;90(51-52):4664.
Type
. Biblical leprosy. Journal of the American Academy of Dermatology. 1993;29(6):1059.
Type
. IFN-gamma, IL-6 and IL-4 modulate M. leprae- or PPD-specific cytotoxic T cells in leprosy patients. Scandinavian journal of immunology. 1993;38(6):551-8.
Type
. Biblical leprosy. Journal of the American Academy of Dermatology. 1993;29(6):1058-9.